Ahmad Farooq Alsayed Hasanain1, Reem Ezzat Mahdy2, Ali Mohamed Abdel-Rahman Mahran3, Ahmed Serag Mahmoud Safwat4, Asmaa Omar Mohamed5, Sherif Mohamed Abdel-Aal6. 1. Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Egypt. Electronic address: a.fh@outlook.com. 2. Department of Internal Medicine (Gastroenterology Unit), Faculty of Medicine, Assiut University, Egypt. 3. Department of Dermatology and Andrology (Andrology Unit), Faculty of Medicine, Assiut University, Egypt. 4. Department of Urology, Faculty of Medicine, Assiut University, Egypt. 5. Department of Clinical Pathology, Faculty of Medicine, Assiut University, Egypt. 6. Department of Diagnostic Radiology, Faculty of Medicine, Assiut University, Egypt.
Abstract
BACKGROUND AND STUDY AIMS: There is a lack of studies on erectile dysfunction (ED) in patients diagnosed with nonalcoholic fatty liver disease (NAFLD). The present study aimed to estimate the prevalence of ED in patients with NAFLD and to determine the independent predictors of ED in these patients. PATIENTS AND METHODS: We conducted a prospective, hospital-based study of 192 consecutive male patients with NAFLD. All patients underwent clinical evaluation; abdominal ultrasonography; test for viral hepatitis markers; and estimation of liver chemistry panel, complete blood count, prothrombin time, serum lipids panel, serum testosterone, and fasting serum levels of glucose, insulin, and C-peptide. RESULTS: The mean age of the study population was 42.4±7.7years (79.1%≥40years). Of the 192 patients with NAFLD, 88 (45.8%) had ED, 28 (14.6%) had metabolic syndrome, 25 (13%) had type-2 diabetes mellitus (DM), and 131 (68.2%) had insulin resistance (IR). The mean level of serum testosterone was 3.17±2.94ng/mL, while the mean insulin resistance index was 2.9±1.7. Mild ED (38.6%) was the most frequent grade of ED. Age≥40years (odds ratio [OR] 6.4; 95% confidence interval [CI] 1.7-24.1; p- 0.006), IR (OR 5.9; 95% CI 1.7-20.6; p- 0.005), and low serum testosterone (OR 5.1; 95% CI 1.5-17.1; p- 0.009) were the predictors of ED. CONCLUSIONS: ED is a common disorder in male patients with NAFLD; both IR and low serum testosterone contribute to its development. Treatment of IR may carry a dual benefit of improving erectile function and decreasing the grade of hepatic steatosis.
BACKGROUND AND STUDY AIMS: There is a lack of studies on erectile dysfunction (ED) in patients diagnosed with nonalcoholic fatty liver disease (NAFLD). The present study aimed to estimate the prevalence of ED in patients with NAFLD and to determine the independent predictors of ED in these patients. PATIENTS AND METHODS: We conducted a prospective, hospital-based study of 192 consecutive male patients with NAFLD. All patients underwent clinical evaluation; abdominal ultrasonography; test for viral hepatitis markers; and estimation of liver chemistry panel, complete blood count, prothrombin time, serum lipids panel, serum testosterone, and fasting serum levels of glucose, insulin, and C-peptide. RESULTS: The mean age of the study population was 42.4±7.7years (79.1%≥40years). Of the 192 patients with NAFLD, 88 (45.8%) had ED, 28 (14.6%) had metabolic syndrome, 25 (13%) had type-2 diabetes mellitus (DM), and 131 (68.2%) had insulin resistance (IR). The mean level of serum testosterone was 3.17±2.94ng/mL, while the mean insulin resistance index was 2.9±1.7. Mild ED (38.6%) was the most frequent grade of ED. Age≥40years (odds ratio [OR] 6.4; 95% confidence interval [CI] 1.7-24.1; p- 0.006), IR (OR 5.9; 95% CI 1.7-20.6; p- 0.005), and low serum testosterone (OR 5.1; 95% CI 1.5-17.1; p- 0.009) were the predictors of ED. CONCLUSIONS: ED is a common disorder in male patients with NAFLD; both IR and low serum testosterone contribute to its development. Treatment of IR may carry a dual benefit of improving erectile function and decreasing the grade of hepatic steatosis.
Authors: Rafael Paternostro; Birgit B Heinisch; Thomas Reiberger; Mattias Mandorfer; Remy Schwarzer; Berit Seeland; Michael Trauner; Markus Peck-Radosavljevic; Arnulf Ferlitsch Journal: Liver Int Date: 2018-02-20 Impact factor: 5.828
Authors: Haifa Maalmi; Christian Herder; Gidon J Bönhof; Klaus Strassburger; Oana-Patricia Zaharia; Wolfgang Rathmann; Volker Burkart; Julia Szendroedi; Michael Roden; Dan Ziegler Journal: Diabetologia Date: 2021-11-20 Impact factor: 10.460
Authors: Valerio Rosato; Mario Masarone; Marcello Dallio; Alessandro Federico; Andrea Aglitti; Marcello Persico Journal: Int J Environ Res Public Health Date: 2019-09-14 Impact factor: 3.390